McKesson earnings up next: Can revenue rebound after Q4 miss?

McKesson is set to report its fiscal first-quarter earnings, with analysts anticipating a rebound in revenue after a significant miss in the previous quarter. Investors will be scrutinizing how the pharmaceutical distributor plans to address increasing competition from direct-to-patient platforms and other sector-wide challenges, despite strong operational execution in prior periods. The stock is rated as a "Buy" by analysts, with a mean price target suggesting a 14% upside.